【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Ovarian Cancer Treatment
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Abbreviations Frequently Used in This Report
2. An Introduction to Ovarian Cancer Therapy
2.1 Overview of Ovarian Cancer
2.1.1 Symptoms of Ovarian Cancer
2.1.2 Risk Factors for Ovarian Cancer
2.1.3 Global Prevalence and Incidence of Ovarian Cancer
2.2 Diagnosing Ovarian Cancer
2.2.1 Laboratory Testing: The Uncertainty of CA 125 Testing
2.2.2 The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
2.2.3 Imaging Studies for Diagnosing Ovarian Cancer
2.3 Treatment Options for Cancer
2.3.1 Chemotherapy
2.3.2 Targeted Therapy
2.3.3 Immunotherapy: Fastest Growing Sector in Cancer Therapy
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Hormone Therapy
2.3.5 First-Line Therapy: Platinum-Taxane Treatment
2.3.6 Second-Line Therapy
2.3.7 Maintenance Therapy
3. Ovarian Cancer: World Market 2015-2025
3.1 Ovarian Cancer Therapies Market, 2014
3.1.1 A Note on Monoclonal Antibodies in this Report
3.2 Ovarian Cancer Therapies Market Forecast, 2015-2025
3.3 Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
3.3.1 Increasing Patient Population
3.3.2 Intense Competition from Generics
3.4 The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
3.5 The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.5.1 Targeted Therapy—Leading Submarket in Ovarian Cancer Therapy by 2025
3.5.2 Chemotherapy—Remains First-Line Treatment for Ovarian Cancer
3.5.3 Immunotherapy—The Fastest Growing Segment in Cancer Therapy
3.5.4 Hormone Therapy—Rare Treatment in Ovarian Cancer
4. Leading Ovarian Cancer Drugs 2014
4.1 Avastin (Roche/Chugai) – The World Market Leader
4.1.1 Avastin Revenue, 2010-2014 – Mixed Growth
4.1.2 Avastin Ovarian Cancer Forecast, 2015-2025
4.2 Lynparza (AstraZeneca)
4.2.1 Lynparza Forecast 2015-2025
4.3 Yondelis (Zeltia/Johnson & Johnson)
4.3.1 Yondelis (Zeltia/Johnson & Johnson): Historical Revenues
4.3.2 Yondelis Forecast 2015-2025
4.4 Other Ovarian Cancer Therapies
5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025
5.1 Regional Breakdown of the World Ovarian Cancer Therapeutics Market
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 The US Ovarian Cancer Drug Therapy Market, 2014
5.2.1 US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
5.3 The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
5.3.1 German Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.2 French Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.3 UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
5.3.3.1 NICE: Guidance for Ovarian Cancer Therapies
5.3.4 Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.5 Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.4 Japan: Growth in Generics – Ovarian Cancer Therapy Market Forecast, 2015-2025
5.5 Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
5.6 Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.7 Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.8 Russian Ovarian Cancer Therapy Market Forecast, 2015-2025
6. Leading Companies in the Ovarian Cancer Therapy Market
6.1 Companies with Exclusivity in 2014
6.2 Johnson & Johnson (J&J)
6.2.1 Sales and Performance Analysis, 2014
6.2.2 Pharmaceutical Segment Sales Analysis, 2014
6.2.2.1 R&D Performance Analysis, 2014
6.2.3 Recent M&A Activity: J&J Acquires Alios BioPharma and Aragon Pharmaceuticals
6.3 Roche
6.3.1 Sales and Performance Analysis, 2014
6.3.2 Pharmaceutical Segment Sales Analysis, 2014
6.3.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.3.2.2 Pharmaceutical Segment R&D Performance Analysis, 2014
6.3.3 Recent M&A Activity
6.4 AstraZeneca
6.4.1 Sales and Performance Analysis, 2014
6.4.2 Pharmaceutical Segment Sales Analysis, 2014
6.4.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.4.2.2 R&D Performance Analysis, 2014
6.4.3 Recent M&A Activity: The Pfizer and AstraZeneca Saga
7. Ovarian Cancer Therapy: Developmental Pipelines 2015
7.1 Ovarian Cancer Phase III Candidates 2015
7.1.1 Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
7.1.1.1 TESARO and Merck to Collaborate: Niraparib and Keytruda
7.1.2 Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
7.1.3 Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
7.1.4 Recentin (AstraZeneca): Promising Results in Phase III
7.1.5 Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
7.1.6 Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
7.1.7 Binimetinib (Array Biopharma): Expected Filing in 2016
7.1.8 Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
7.1.9 Virgil (Gradalis): Autologous Tumour Cell Vaccine
7.1.10 Farletuzumab (Eisai): Failure in Phase III
7.2 Ovarian Cancer Phase II Candidates 2015
7.2.1 CVac (Prima BioMed): MUC-1 Cancer Vaccine
7.2.2 SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
7.2.3 Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
7.2.4 Reolysin (Oncolytics Biotech)
7.2.5 SGI110 (Astex Pharmaceuticals)
7.2.6 OvaRex (Quest PharmaTech)
7.2.7 Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
7.2.8 Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
7.2.9 Cyramza (Eli Lilly): Expanding Approved Indications
7.2.10 EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
7.2.11 Ganetespib and Elesclomol (Synta Pharmaceuticals)
7.2.12 ENMD-2076 (CASI Pharmaceuticals)
7.2.13 GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
7.2.14 Epacadostat (Incyte Corporation): IDO1 Inhibitor
7.2.15 AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
7.2.16 Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
7.2.17 Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
7.2.18 Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
7.2.19 Zybrestat (OXiGENE): Vascular Disrupting Agent
7.2.20 Yervoy (Bristol-Myers Squibb)
7.2.21 Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
7.2.22 Voxtalisib with Pimasertib (Sanofi and Merck Serono)
7.2.23 Eli Lilly’s Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab & Ralimetinib
7.2.24 MK2206 (Merck & Co.): AKT Inhibitor
7.2.25 A6 Peptide (Angstrom Pharma)
7.2.26 Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
7.3 Ovarian Cancer Phase II Candidates 2015
7.3.1 VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
7.3.2 MEDI4736 (AstraZeneca)
7.3.3 OVax (AVAX Technologies)
7.3.4 ME-344 (Novogen)
7.3.5 DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies
8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025
8.1 SWOT Analysis of the Ovarian Cancer Therapeutics Market
8.1.1 Strengths and Weaknesses of the Market
8.1.2 The Rising Incidence of Cancer
8.1.3 Drug Development Challenges
8.2 Opportunities and Threats for the Market
8.2.1 Advances in Research Open the Doors for Personalised Therapy
8.3 Regulations and Pricing Restrictions
8.4 STEP Analysis of the Ovarian Cancer Therapy Market
8.4.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.4.2 Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
8.4.3 Economic Factors: Cost Cutting in the EU and the US
8.4.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
8.5 Porter’s Five Forces Analysis of the Ovarian Cancer Therapeutics Market
8.5.1 Rivalry Among Competitors
8.5.2 Threat of New Entrants
8.5.3 Power of Suppliers
8.5.4 Power of Buyers
8.5.5 Threat of Substitutes
9. Research Interviews
9.1 Interview with Prof. Dror Harats, CEO, VBL Therapeutics
9.1.1 Outlook for VB-111 in the Ovarian Cancer Market
9.1.2 Drivers and Restraints in the Ovarian Cancer Market
9.1.3 Trends in the Ovarian Cancer Market
9.1.4 Outlook for VBL Therapeutics in the Oncology Market
9.2 Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
9.2.1 Outlook for CVac in the Ovarian Cancer Market
9.2.2 The Ovarian Cancer Market
9.2.3 Trends in the Ovarian Cancer Market
9.2.4 Outlook for Prima BioMed in the Oncology Market
9.3 Interview with a Representative of OXiGENE
9.3.1 Outlook for Zybrestat in the Ovarian Cancer Market
9.3.2 The Ovarian Cancer Market in 2015
9.3.3 Trends in the Ovarian Cancer Market, 2015-2025
9.3.4 Outlook for OXiGENE in the Oncology Market
10. Conclusions from the Research and Analysis
10.1 The World Ovarian Cancer Therapeutics Market in 2014
10.1.1 Leading National Markets to 2025
10.2 Trends in the Industry
10.2.1 Growing Interest in Personalised Therapy
10.2.2 Multiple Late-Stage Pipeline Drugs
10.3 Concluding Remarks
【レポート販売概要】
■ タイトル：卵巣がん治療薬の世界市場：企業動向、研究開発、収益予測■ 英文：Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
: Recently Approved Treatments Give High Market Potential
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5081914
■ 調査対象地域：グローバル
- 医療用複合材料の世界市場：繊維複合材、高分子・金属複合材、高分子・セラミック複合材About Medical Composite Materials Medical composite materials are used in place of steel, plastic, and aluminum for the manufacture of customized and complex products like advanced orthopedic devices, prosthetics, and body implants. They are also used in dental applications such as restoration and filling of natural teeth. These materials offer the following benefits: • High strength-to-weight rat …
- アメリカの講義収録ソリューション市場2017-2021ABSTRACTAbout Lecture Capture Solutions Lecture capture solutions refer to technologies that capture, create, manage, broadcast, and archive lectures. These technologies also synchronize the recorded content with a visual aid and either stream it live or archive it for future on-demand viewing on a computer or mobile device. In addition, the ability of these technologies to add colors and interact …
- 世界におけるリテールバンキング（銀行）のIT支出市場：ハードウェア、ソフトウェア、ITサービス、技術別分析About Retail Banking IT Retail banking IT spending occupies a major share in the total IT spending by banks worldwide. Apart from spending on core hardware, software, and services, retail banks spend on a number of emerging technologies such as core banking, analytical technologies, internal operations, online banking, mobile banking, and channel management. Innovation in banking technologies has …
- Linn Energy, LLC：石油・ガスの開発・生産動向及びコスト分析– Q1, 2013Linn Energy, LLC Oil & Gas Exploration and Production Operations and Cost Analysis – Q1, 2013 Summary Linn Energy, LLC Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- ヒトインスリンの世界市場：ヒトインスリン薬、ヒトインスリン・デリバリーデバイスThe global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery dev …
- サウジアラビアの鉄道インフラ支出市場2016-2020About Railway Infrastructure Spending Market in Saudi Arabia Before 2010, Saudi Arabia had a small railway network, with a 278.9 miles passenger line and a 556-km freight line, linking Riyadh and Gulf port of Damam via Haradh. Until 2010, the railways were the least developed means of transport in the country. However, since 2010, investments in the expansion of new railway lines have surged becau …
- DCモータドライブの世界市場2015-2019About DC drives A drive is an adjustable device that regulates the speed and torque of motors by varying electrical frequency and voltage. Drives are broadly classified into two: AC drives and DC drives. AC drives are used to control the speed of AC electric motors while DC drives are used to control the speed of DC electric motors. DC drives consist of thyristor-based controllers that help in con …
- 肝機能不全(Hepatic Insufficiency)：世界の治験レビュー（2015年上半期版）Hepatic Insufficiency Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Hepatic Insufficiency Global Clinical Trials Review, H1, 2015" provides data on the Hepatic Insufficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Insufficiency. It includes an overview of the trial numbers and the …
- 世界の軍事シミュレーションおよび仮想訓練市場（2014-2024）：市場規模、動因Synopsis This report provides readers with a comprehensive analysis of the Military Simulation and Virtual Training market through 2013-2023, including highlights of the demand drivers and growth stimulators for Military Simulation and Virtual Training. It also provides an insight on the spending pattern and modernization pattern in different regions around the world. Summary The global military s …
- ｏ－キシレンの世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world orthoxylene market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true insig …
- オートクレーブ養生気泡コンクリートの世界市場：用途別、エンドユーザー別（住宅、商業ビル、インフラ）、地域別予測Global Autoclaved Aerated Concrete Market to reach USD xxxx billion by 2025. Global Autoclaved Aerated Concrete Market valued approximately USD xxxx billion in 2016 is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2017-2025. The global autoclaved aerated concrete market is witnessing significant growth, due to increasing industrialization and accelerated …
- 計装バルブ及び継手の世界市場予測（～2022年）：バルブ、継手、空気圧式アクチュエータThe global instrumentation valves & fittings market is expected to be worth USD 4.31 Billion by 2022, growing at a CAGR of 4.6% during the forecast period. The major drivers for the instrumentation valves & fittings market are growth in fracking and utilizing 1” to 6” brass or copper valves, expanding process instrumentation and automation, and Increase in consumption of instrumentation valves due …
- 音声認識ソフトの世界市場2016-2020About Speech Recognition Software A speech recognition software identifies words spoken by an individual or speaker into a microphone, converts them into a computer-readable format, and responds automatically. These software applications recognize speech in multiple languages. These applications are used both by individual consumers and enterprises in the healthcare; banking, financial services, a …
- 世界の鉱山産業における水処理・廃水処理装置市場About Water and Waste Water Market in Mining Industry Water is extremely important in the processing of ore extracted in the Mining industry. Many of the mining facilities in the world are located in regions with a low source of water. These facilities face water-related issues arising at almost every stage of the mining process. Therefore, the emphasis is on refining and reusing available water, …
- 世界の油料作物産業分析：Analyzing the Global Oil Crops IndustryThe global oil crops industry expanded by nearly 13% in 2011 and by 2016 the industry is expected to rise by over 40% overall, which indicates a slowdown in the overall growth rate of the industry. The Asia-Pacific region accounted for almost 65% of the total industry value at the moment and is expected to continue with the same momentum in the future. The oil crops market values the supply (consu …
